A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)

NCT00517530 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
134
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Hoffmann-La Roche